Question 1

What is Drospirenone and Ethinyl Estradiol used for?

Accepted Answer

Drospirenone and Ethinyl Estradiol supplements progesterone activity, used in contraception and hormone therapy.

Question 2

Is there a generic for Drospirenone and Ethinyl Estradiol?

Accepted Answer

Yes. 18 ANDAs filed at FDA, 11 generic manufacturers currently shipping.

Question 3

How much does my plan pay for Drospirenone and Ethinyl Estradiol?

Accepted Answer

Across 329 Part D plans, Drospirenone and Ethinyl Estradiol averages $0.666/unit (NADAC). Lowest available: $0.154/unit. Highest in distribution: $5.85/unit.

Question 4

Is Drospirenone and Ethinyl Estradiol on the FDA shortage list?

Accepted Answer

Drospirenone and Ethinyl Estradiol has been discontinued by its manufacturer(s).

Question 5

What drug class is Drospirenone and Ethinyl Estradiol in?

Accepted Answer

Drospirenone and Ethinyl Estradiol is in the Progestin class. See related drugs in this class at /class/progestin.

Question 6

What is the brand name for Drospirenone and Ethinyl Estradiol?

Accepted Answer

Drospirenone and Ethinyl Estradiol is sold under brand names: Jasmiel, Lo-Zumandimine, Nikki, OCELLA, Syeda, Vestura, Yasmin, Yaz, Zumandimine.

Question 7

Is Jasmiel the same as Drospirenone and Ethinyl Estradiol?

Accepted Answer

Yes. Jasmiel is a brand name for Drospirenone and Ethinyl Estradiol. The generic version is identical in active ingredient, dose, and FDA-approved indications. Pricing differs substantially: generic Drospirenone and Ethinyl Estradiol typically prices well below brand Jasmiel.

Question 8

Why is there a spread between low and average NADAC for Drospirenone and Ethinyl Estradiol?

Accepted Answer

The 4× spread between lowest NADAC ($0.154/unit on generic NDCs) and average NADAC ($0.666/unit across all NDCs) reflects that brand-tier NDCs are still in distribution at higher prices. Most plans haven't migrated utilization toward the generic NDCs yet. For plans, this is the structural source of within-molecule savings opportunity.

Question 9

What can I switch to instead of Drospirenone and Ethinyl Estradiol?

Accepted Answer

Same-class alternatives include: Desogestrel and Ethinyl Estradiol, Desogestrel and Ethinyl Estradiol and Ethinyl Estradiol, Ethynodiol Diacetate and Ethinyl Estradiol. Whether substitution is clinically appropriate depends on patient indication, dose schedule, and contraindications — that is a P&T committee decision. The federal data shows cost and competition; clinical equivalence is not asserted here.

Question 10

Why isn't Drospirenone and Ethinyl Estradiol cheaper if there's no PA friction?

Accepted Answer

Drospirenone and Ethinyl Estradiol has 11 generic manufacturers and zero prior-authorization barriers across 329 Part D plans. Why it isn't already cheaper on most plans: tier placement and PBM contract structure, not clinical or supply factors. Moving the molecule to a lower formulary tier captures the savings — see leak report for sizing.

Question 11

When did the most recent Drospirenone and Ethinyl Estradiol generic get approved?

Accepted Answer

The most recent ANDA approval for Drospirenone and Ethinyl Estradiol is HETERO LABS LTD (ANDAANDA213034, approved 2020-01-24).

Question 12

When was Drospirenone and Ethinyl Estradiol first FDA approved?

Accepted Answer

Drospirenone and Ethinyl Estradiol received its first FDA approval on 2001-05-11.

Drospirenone and Ethinyl Estradiol (Jasmiel)

Questions a plan sponsor actually asks.

Related questions.

Same class. Different math.

Sources · every number above traces back.